GENE ONLINE|News &
Opinion
Blog

Gene Editing
Treating Common Heart Disease with CRISPR-Cas9 Gene Editing
2022-12-27
Verve and Vertex Agree to Co-Develop In Vivo Gene Editing Program for Liver Disease
2022-07-21
Verve Cleared to Test Gene Editing Drug for Heart Disease in Humans
2022-05-12
TALED Tool Launches a New Era of Mitochondrial Genome Editing
2022-05-03
CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label
2022-04-27
FDA Announces Draft Guidances on Genome Editing and CAR T Cell Therapy
2022-03-25
China Pushes for Faster Approval for Gene-Edited Crops
2022-02-15
What If Our Body’s Power Station Goes Wrong? Gene Therapy May Help
2022-02-15
GeneOnline’s Pick: Novel Biotechnologies that Made a Splash in 2021
2022-01-27
GeneOnline’s Top 10 Editor’s Picks for 2021
2021-12-23
Harnessing the potential of CRISPR-Cas9 for Gut Microbiome Gene Editing
2021-11-29
Study Advocates Cautious Application of CRISPR in Designing Therapeutics
2021-11-22
Chroma Medicine Debuts with High Hopes for “Game-Changing” Epigenetic Genome Editors
2021-11-17
Moderna Enters Gene Editing Market with Metagenomi Collaboration
2021-11-03
New Age Gene Editors Take Us Closer to CRISPR-Based Gene Therapy
2021-10-28
1 2 3 6
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!